• M Shulman, J E Harris, T R Lubenow, H A Nath, and A D Ivankovich.
• Department of Anesthesiology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA. rmccarth@rpslmc.edu
• Clin J Pain. 2000 Dec 1; 16 (4): 304-9.

ObjectiveTo compare pain relief in metastatic pancreatic cancer patients between neurolytic celiac plexus block (NCPB) and epidural 5% butamben suspension (EBS), a material-based delivery system of a local anesthetic that produces a long-lasting differential nerve block.DesignOpen-label patient-selected parallel groups.SettingUrban tertiary care medical center.PatientsTwenty-four adult patients with metastatic pancreatic cancer experiencing pain uncontrolled by systemic opioids who were referred to a multidisciplinary pain clinic for interventional therapy.InterventionsAntecrural NCPB-block with ethanol and epidural 5% butamben suspension injections.MeasuresSubjective global pain relief assessments on a 0-100% scale were made weekly for 4 weeks and then monthly. Change in opioid use postintervention.ResultsEight patients had a single NCPB and three patients had two NCPB. Four of the former and two of the latter had successful pain relief defined to be a more than 75% reduction in pain when compared with pretreatment maintained for more than 4 weeks or until death (if less than 4 weeks). Thirteen patients received EBS in divided doses. Eleven patients received a cumulative EBS dose of 5 grams, one patient received a cumulative EBS dose of 2.5 grams, and one patient received a cumulative EBS dose of 8.75 grams. Nine of the eleven patients and each of the other two patients had successful pain relief. The overall incidence (85% EBS vs. 55% NCPB), the duration of successful pain relief, and the percent reduction in opioid use did not differ between the two groups. There were no serious complications.ConclusionEBS appears to be a safe and effective alternative to NCPB in the treatment of pancreatic cancer pain.

28 keywords...

hide…